Literature DB >> 23968309

Treatment of neonatal progressive ventricular dilatation: a single-centre experience.

A J Brouwer1, F Groenendaal1, K S Han2, L S de Vries1.   

Abstract

OBJECTIVE: To describe our experience with a cohort of 295 infants with progressive ventricular dilatation occurring in the antenatal or neonatal period.
METHODS: A search was performed in our cranial ultrasound database. All records and images of infants in whom an imaging diagnosis of progressive ventricular dilatation had been made were retrieved. In addition, modes of treatment were analysed.
RESULTS: Between February 1991 and March 2012, 295 neonates were admitted to our level 3 neonatal intensive care unit (NICU), and developed progressive ventricular dilatation for which they required intervention. In the majority of these infants, progressive ventricular dilatation developed following IVH grade III or IV (240/295; 81%) of whom 214/240 (89%) were preterms. Temporary treatment with lumbar punctures and punctures from ventricular reservoirs was sufficient for the majority of the preterms. A ventricular reservoir was inserted in 216/295 infants (73%). The overall infection rate was low (6%). A ventriculoperitoneal shunt (VP shunt) was inserted in 32% of the whole cohort, revision within 3 months was necessary in 20%, and shunt-related infection occurred in 12%.
CONCLUSIONS: This large, single-centre cohort study reports the management of progressive ventricular dilatation in newborn infants. We have shown that with our approach, complications stay within acceptable limits.

Entities:  

Keywords:  Hydrocephalus; IVH; PHVD; preterm

Mesh:

Year:  2013        PMID: 23968309     DOI: 10.3109/14767058.2013.796167

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  7 in total

1.  Neurodevelopmental and Behavioral Outcomes in Extremely Premature Neonates With Ventriculomegaly in the Absence of Periventricular-Intraventricular Hemorrhage.

Authors:  Athina Pappas; Ira Adams-Chapman; Seetha Shankaran; Scott A McDonald; Barbara J Stoll; Abbot R Laptook; Waldemar A Carlo; Krisa P Van Meurs; Susan R Hintz; Martha D Carlson; Jane E Brumbaugh; Michele C Walsh; Myra H Wyckoff; Abhik Das; Rosemary D Higgins
Journal:  JAMA Pediatr       Date:  2018-01-01       Impact factor: 16.193

2.  Posthemorrhagic ventricular dilatation in preterm infants: When best to intervene?

Authors:  Lara M Leijser; Steven P Miller; Gerda van Wezel-Meijler; Annemieke J Brouwer; Jeffrey Traubici; Ingrid C van Haastert; Hilary E Whyte; Floris Groenendaal; Abhaya V Kulkarni; Kuo S Han; Peter A Woerdeman; Paige T Church; Edmond N Kelly; Henrica L M van Straaten; Linh G Ly; Linda S de Vries
Journal:  Neurology       Date:  2018-01-24       Impact factor: 9.910

3.  Monitoring intraventricular vancomycin for ventriculostomy access device infection in preterm infants.

Authors:  Jaya Madhura Parasuraman; Mahableshwar Albur; Greg Fellows; Axel Heep
Journal:  Childs Nerv Syst       Date:  2017-10-24       Impact factor: 1.475

4.  Surgical intervention for hydrocephalus in infancy; etiology, age and treatment data in a Dutch cohort.

Authors:  J C Holwerda; E J van Lindert; D R Buis; E W Hoving
Journal:  Childs Nerv Syst       Date:  2019-08-12       Impact factor: 1.475

5.  Population Pharmacokinetics of Intraventricular Vancomycin in Neonatal Ventriculitis, A Preterm Pilot Study.

Authors:  Jaya Madhura Parasuraman; Frank Kloprogge; Joseph Frank Standing; Mahableshwar Albur; Axel Heep
Journal:  Eur J Pharm Sci       Date:  2020-11-12       Impact factor: 4.384

Review 6.  Mechanisms of neuroinflammation in hydrocephalus after intraventricular hemorrhage: a review.

Authors:  Katherine G Holste; Fan Xia; Fenghui Ye; Richard F Keep; Guohua Xi
Journal:  Fluids Barriers CNS       Date:  2022-04-01

7.  Management of Post-hemorrhagic Ventricular Dilatation in the Infant Born Preterm.

Authors:  Mohamed El-Dib; David D Limbrick; Terrie Inder; Andrew Whitelaw; Abhaya V Kulkarni; Benjamin Warf; Joseph J Volpe; Linda S de Vries
Journal:  J Pediatr       Date:  2020-07-30       Impact factor: 4.406

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.